However, treatment with CXCR4 inhibitor AMD3100 (Fig. 3d) and disruption of actin cytoskeleton with cytochalasin D (CYD) treatment abrogated CML-stromal interaction. The gene discussed is CXCR4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.